ES2114605T5 - Metodo anticonceptivo que emplea un antagonista de progesterona competitivo y nuevos compuestos utilizados en el. - Google Patents

Metodo anticonceptivo que emplea un antagonista de progesterona competitivo y nuevos compuestos utilizados en el.

Info

Publication number
ES2114605T5
ES2114605T5 ES93909968T ES93909968T ES2114605T5 ES 2114605 T5 ES2114605 T5 ES 2114605T5 ES 93909968 T ES93909968 T ES 93909968T ES 93909968 T ES93909968 T ES 93909968T ES 2114605 T5 ES2114605 T5 ES 2114605T5
Authority
ES
Spain
Prior art keywords
competitive progesterone
compounds used
new compounds
progesterone antagonist
contraceptive method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909968T
Other languages
English (en)
Other versions
ES2114605T3 (es
Inventor
Krzysztof Chwalisz
Karin Schmidt-Gollwitzer
Eckhard Ottow
Ulrich Klar
Horst Michna
Walter Elger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25914813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2114605(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE4216004A external-priority patent/DE4216004B4/de
Priority claimed from DE19924216003 external-priority patent/DE4216003A1/de
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2114605T3 publication Critical patent/ES2114605T3/es
Publication of ES2114605T5 publication Critical patent/ES2114605T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nozzles (AREA)
  • Mixers With Rotating Receptacles And Mixers With Vibration Mechanisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

LOS ANTAGONISTAS DE LA PROGESTERONA COMPETITIVOS, QUE INCLUYEN DOS NUEVOS ESTEROIDES, A SABER, 11(BETA)-19-[4(CIANOFENIL)-O-FENILEN]-17(BETA)-HIDROXI-17(ALFA)-(3-HIDROXIPROP-1(Z)ENIL)-4-ANDROSTEN-3-ONA Y 11(BETA)-19-[4-(3-PIRIDINIL)-O-FENILEN]17(BETA)-HIDROXI-17(ALFA)-(3-HIDROXI-PROP-1(Z)-ENIL)-4-ANDROSTEN-3-ONA, INHIBEN LA FORMACION DE GLANDULAS ENDOMETRIALES A POR DEBAJO DE SU DOSIS INHIBIDORA DE LA OVULACION Y LA DOSIS ABORTIVA, Y POR TANTO LAS MUJERES LOS PUEDEN UTILIZAR COMO ANTICONCEPTIVOS ORALES SIN QUE ESTO AFECTE DE MANERA ADVERSA AL CICLO MENSTRUAL Y SIN RIESGO DE ABORTO DEL HUEVO FERTILIZADO PREVIAMENTE IMPLANTADO O DEL FETO.
ES93909968T 1992-05-12 1993-05-12 Metodo anticonceptivo que emplea un antagonista de progesterona competitivo y nuevos compuestos utilizados en el. Expired - Lifetime ES2114605T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4216004A DE4216004B4 (de) 1992-05-12 1992-05-12 Verwendung kompetitiver Progesteronantagonisten
DE19924216003 DE4216003A1 (de) 1992-05-12 1992-05-12 Dissoziierte kompetitive Progesteronantagonisten

Publications (2)

Publication Number Publication Date
ES2114605T3 ES2114605T3 (es) 1998-06-01
ES2114605T5 true ES2114605T5 (es) 2003-04-16

Family

ID=25914813

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909968T Expired - Lifetime ES2114605T5 (es) 1992-05-12 1993-05-12 Metodo anticonceptivo que emplea un antagonista de progesterona competitivo y nuevos compuestos utilizados en el.

Country Status (29)

Country Link
US (5) US5439913A (es)
EP (1) EP0639970B2 (es)
JP (1) JPH07506582A (es)
KR (1) KR100253922B1 (es)
CN (1) CN1059446C (es)
AT (1) ATE162712T1 (es)
AU (1) AU687000B2 (es)
BG (1) BG61965B1 (es)
BR (1) BR9306354A (es)
CA (1) CA2135608C (es)
CZ (1) CZ290612B6 (es)
DE (1) DE69316747T3 (es)
DK (1) DK0639970T4 (es)
ES (1) ES2114605T5 (es)
FI (1) FI112167B (es)
GR (1) GR3026316T3 (es)
HU (1) HUT68061A (es)
IL (1) IL105684A (es)
MX (1) MX9302748A (es)
MY (1) MY108866A (es)
NO (1) NO307691B1 (es)
NZ (1) NZ252154A (es)
PH (1) PH29913A (es)
PL (1) PL173337B1 (es)
RO (1) RO116769B1 (es)
RU (1) RU2137476C1 (es)
SK (1) SK282531B6 (es)
UA (1) UA39934C2 (es)
WO (1) WO1993023020A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
DE4344463A1 (de) * 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
FR2718138B1 (fr) * 1994-04-01 1996-04-26 Roussel Uclaf Nouveaux stéroïdes comportant en position 20 une chaîne aminosubstituée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les renfermant.
DE4417880A1 (de) * 1994-05-18 1995-11-23 Schering Ag 19,11beta-Überbrückte 18-Nor-Steroide, Verfahren zu ihrer Herstellung, diese Steroide enthaltende Arzneimittel sowie deren Verwendung zur Herstellung von Arzneimitteln
DE59511071D1 (de) * 1994-10-24 2007-01-25 Schering Ag Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle
ZA9510926B (en) 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
DE19652408C2 (de) * 1996-12-06 2002-04-18 Schering Ag Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln
CA2255130A1 (en) 1997-12-16 1999-06-16 Archer Daniels Midland Company Process for making granular l-lysine feed supplement
US20020169205A1 (en) * 1998-09-29 2002-11-14 Krzysztof Chwalisz Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents
MXPA02002186A (es) 1999-08-31 2002-09-02 Jenapharm Gmbh Mesoprogestinas (moduladores del receptor de progesterona) como un componente de los anticonceptivos femeninos.
US7317027B2 (en) * 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
RU2006114791A (ru) * 2003-10-01 2007-11-27 Янссен Фармацевтика Н.В. (Be) Продленные режимы трехфазных контрацептивов
US20060205700A1 (en) * 2005-03-09 2006-09-14 May Flavia S Non invasive method for prevention and treatment of cancer
CA2673128C (en) 2006-10-24 2018-07-03 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
DE102007049630A1 (de) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007023614A1 (de) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2070909A1 (de) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Nichtsteroidale Progesteronrezeptor-Modulatoren
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
JP5894143B2 (ja) 2010-03-22 2016-03-23 リプロス セラピューティクス インコーポレイテッド 抗黄体ホルモンの無毒送達のための組成物および方法
PL2576582T3 (pl) 2010-05-26 2020-06-29 Corcept Therapeutics, Inc. Leczenie dystrofii mięśniowej
US9381193B2 (en) * 2011-04-01 2016-07-05 Washington University Contraceptive methods and compositions
EP2868321A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for inhibiting autocrine HCG production in adult human cells
EP2868323A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
AU2016226451B2 (en) 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
AU2016243625B2 (en) 2015-03-30 2020-09-10 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
EP3335043B1 (en) 2015-08-13 2021-03-31 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
CA3011728A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
WO2018236749A2 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. METHODS OF TREATING NEURO-EPITHELIAL TUMORS USING GLUCOCORTICOID RECEPTOR SELECTIVE MODULATORS
CA3205462A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE219447C (es) *
DE283428C (es) * 1913-12-10 1915-04-15
US3890356A (en) 1973-03-26 1975-06-17 Richardson Merrell Inc 7-Alkyl-{66 {hu 3,5{b -steroids
US4000273A (en) 1973-11-01 1976-12-28 Richardson-Merrell Inc. Method for the control of fertility
US3928398A (en) 1973-11-01 1975-12-23 Richardson Merrell Inc Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
US4352751A (en) 1979-09-10 1982-10-05 Analytical Radiation Corporation Species-linked diamine triacetic acids and their chelates
US4416622A (en) * 1980-11-25 1983-11-22 F. L. Smidth & Co. Method and plant such as a kiln plant for treating granular or pulverous raw material
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4416822A (en) 1982-07-09 1983-11-22 The Upjohn Company 17β-Difluoromethyl steroids
IL68222A (en) 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
ES8502612A1 (es) 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
DE3324235A1 (de) 1983-07-01 1985-01-10 Schering AG, 1000 Berlin und 4709 Bergkamen Neue komplexbildner, komplexe und komplexsalze
AU572589B2 (en) 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US4859451A (en) 1984-10-04 1989-08-22 Salutar, Inc. Paramagnetic contrast agents for MR imaging
US5087439A (en) 1984-11-13 1992-02-11 Salutar, Inc. Paramagnetic metal-diethylenetriamine-pentaacetic acid partial amide complexes for magnetic resonance imaging
US4826673A (en) 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
DE3533175A1 (de) * 1985-09-13 1987-03-19 Schering Ag Antigestagene zur verschiebung der endometrialen reifung
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5039512A (en) 1986-08-04 1991-08-13 Salutar, Inc. NMR imaging with paramagnetic polyvalent metal salts of poly-(acid-alkylene-amino)-alkanes
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
US4994259A (en) 1987-05-08 1991-02-19 Salutar, Inc. Improvement in the method of NMR imaging employing a manganese II chelates of N,N'-bis[pyridoxal-alkylene (or cycloalkylene) (or arylene)]-N,N'-diacetic acid derivatives
US5198208A (en) 1987-07-16 1993-03-30 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
US5399340A (en) 1987-09-24 1995-03-21 Schering Aktiengesellschaft Use of amide complex compounds
DE3805064A1 (de) * 1988-02-18 1989-10-05 Hoechst Ag Pharmazeutische zubereitungen zur geburtseinleitung, fuer den schwangerschaftsabbruch und zur verwendung als kontrazeptivum
US5137711A (en) 1988-07-19 1992-08-11 Mallickrodt Medical, Inc. Paramagnetic dtpa and edta alkoxyalkylamide complexes as mri agents
US5011925A (en) 1989-03-09 1991-04-30 Mallinckrodt, Inc. Morpholinoamido EDTA derivatives
US5384108A (en) 1989-04-24 1995-01-24 Mallinckrodt Medical, Inc. Magnetic resonance imaging agents
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
US5077037A (en) 1990-08-03 1991-12-31 Mallinckrodt Medical, Inc. Novel compositions for magnetic resonance imaging
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
IE71203B1 (en) 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
WO1993021926A1 (en) 1992-05-06 1993-11-11 Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding
US5330743A (en) 1992-11-12 1994-07-19 Magnetic Research, Inc. Aminosaccharide contrast agents for magnetic resonance images
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization

Also Published As

Publication number Publication date
SK134794A3 (en) 1998-05-06
US6340688B1 (en) 2002-01-22
EP0639970A1 (en) 1995-03-01
MY108866A (en) 1996-11-30
BG99178A (bg) 1995-05-31
RU94046068A (ru) 1996-10-20
CZ290612B6 (cs) 2002-09-11
AU4067393A (en) 1993-12-13
FI945289A0 (fi) 1994-11-10
AU687000B2 (en) 1998-02-19
PL173337B1 (pl) 1998-02-27
BG61965B1 (bg) 1998-11-30
DK0639970T3 (da) 1998-09-21
EP0639970B2 (en) 2002-11-06
WO1993023020A1 (en) 1993-11-25
CA2135608C (en) 2007-04-10
IL105684A0 (en) 1993-09-22
ES2114605T3 (es) 1998-06-01
DE69316747T2 (de) 1998-09-24
NO944308D0 (no) 1994-11-11
CZ278094A3 (en) 1995-02-15
SK282531B6 (sk) 2002-10-08
DE69316747T3 (de) 2003-04-10
US20030191102A1 (en) 2003-10-09
US7297702B2 (en) 2007-11-20
NO307691B1 (no) 2000-05-15
KR100253922B1 (en) 2000-09-01
NO944308L (no) 1995-01-11
ATE162712T1 (de) 1998-02-15
FI112167B (fi) 2003-11-14
FI945289A (fi) 1994-11-10
CN1059446C (zh) 2000-12-13
RO116769B1 (ro) 2001-06-29
DK0639970T4 (da) 2003-02-10
US20050026885A1 (en) 2005-02-03
US6608074B2 (en) 2003-08-19
PH29913A (en) 1996-09-16
EP0639970B1 (en) 1998-01-28
UA39934C2 (uk) 2001-07-16
JPH07506582A (ja) 1995-07-20
GR3026316T3 (en) 1998-06-30
HUT68061A (en) 1995-05-29
IL105684A (en) 1998-08-16
CN1087643A (zh) 1994-06-08
US6790853B2 (en) 2004-09-14
CA2135608A1 (en) 1993-11-25
DE69316747D1 (de) 1998-03-05
US20020058649A1 (en) 2002-05-16
BR9306354A (pt) 1998-06-30
RU2137476C1 (ru) 1999-09-20
MX9302748A (es) 1994-02-28
US5439913A (en) 1995-08-08
NZ252154A (en) 1996-04-26

Similar Documents

Publication Publication Date Title
ES2114605T5 (es) Metodo anticonceptivo que emplea un antagonista de progesterona competitivo y nuevos compuestos utilizados en el.
ES2174920T3 (es) Producto de combinacion para la contracepcion que contiene agentes antagonistas de progesterona y un agente gestageno.
ATE215081T1 (de) Gonadotropin releasing hormon- antagonisten
DE69942610D1 (de) Die bindung von integrinen zu deren rezeptoren verhindernde verbindungen
ATE383153T1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
FI915913A (fi) Ehkäisyvalmiste, joka sisältää ainoastaan progestogeenia
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
EP1159965A3 (en) Method of preventing or inhibiting fertilization

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 639970

Country of ref document: ES